New lawsuit raises questions about the future of pharmacy benefit managers and patient access
Nashville, Tennessee, 28 May 2026 – CVS Health has filed a lawsuit against the state of Tennessee after lawmakers approved a new law aimed at restricting the role of pharmacy benefit managers in the healthcare system. The legal battle is drawing nationwide attention as states continue increasing scrutiny on how prescription drug pricing and pharmacy operations are managed.
The Tennessee law, known as the Fair Rx Act, prevents companies from owning both a pharmacy benefit manager and retail pharmacies within the state. Pharmacy benefit managers, commonly called PBMs, work as intermediaries between insurance companies, drug manufacturers, and pharmacies to negotiate medication prices and manage prescription drug benefits.
CVS argues that the law unfairly targets its business structure because the company operates retail pharmacies while also owning CVS Caremark, one of the largest PBMs in the United States. According to the company, the legislation could force the closure of more than 100 CVS pharmacy locations across Tennessee and affect access to healthcare services for millions of customers.
State lawmakers supporting the bill say the measure is designed to create fair competition and protect independent pharmacies. Officials claim vertically integrated healthcare companies have too much control over prescription pricing, reimbursement systems, and pharmacy operations. Supporters also argue that smaller pharmacies have struggled financially due to reimbursement practices linked to PBMs.
The legal challenge follows a similar dispute in Arkansas, where lawmakers passed comparable legislation in 2025. That law also faced lawsuits from CVS and other PBM operators, with a federal judge temporarily blocking enforcement while court proceedings continue.
Industry analysts say the Tennessee lawsuit could become a major test case for the future regulation of pharmacy benefit managers in the United States. PBMs have faced growing criticism in recent years over drug pricing transparency, reimbursement policies, and market influence within the healthcare supply chain.
Healthcare experts note that the PBM industry is highly concentrated, with a few large companies controlling a significant portion of prescription drug management nationwide. Critics believe this concentration limits competition and impacts independent pharmacies, while supporters argue PBMs help negotiate lower drug prices and improve efficiency in healthcare spending.
CVS has maintained that the Tennessee law could reduce patient access to medications and pharmacy services, especially in rural communities. The company also argues that the legislation may violate constitutional protections related to interstate commerce and federal healthcare regulations.
The debate highlights broader tensions within the healthcare industry as policymakers attempt to balance affordability, competition, patient access, and corporate influence. Across the country, several states are exploring stricter oversight of pharmacy benefit managers as concerns over prescription drug costs continue rising.
Legal experts believe the outcome of the Tennessee case may influence future healthcare regulations and determine how states approach PBM reform moving forward. The case could also affect major pharmacy chains, insurers, and healthcare companies operating under vertically integrated business models.
As healthcare costs remain a growing concern for consumers and businesses alike, the battle between CVS and Tennessee reflects the larger national conversation around transparency, competition, and the future of prescription drug management in America.
